ReclutandoNCT03486873
Long-term Safety and Efficacy Extension Study for Participants With Advanced Tumors Who Are Currently on Treatment or in Follow-up in a Pembrolizumab (MK-3475) Study (MK-3475-587/KEYNOTE-587)
Fase 3Merck Sharp & Dohme LLC
Condiciones: Solid Tumors, Hematologic Malignancies
Sedes en Guadalajara: Centro de Inmuno Oncología de Occidente SA de CV ( Site 1115)
Ver registro oficial ↗ReclutandoNCT04613596
Phase 2 Trial of Adagrasib Monotherapy and in Combination With Pembrolizumab and a Phase 3 Trial of Adagrasib in Combination in Patients With a KRAS G12C Mutation KRYSTAL-7
Fase 2 / Fase 3Mirati Therapeutics Inc.
Condiciones: Advanced Non-Small Cell Lung Cancer, Metastatic Non-Small Cell Lung Cancer
Sedes en Guadalajara: Cancer Treatment Clinic and Clinical Trials · Local Institution - Unk070
Ver registro oficial ↗ReclutandoNCT05646862
A Study Evaluating the Efficacy and Safety of Inavolisib Plus Fulvestrant Compared With Alpelisib Plus Fulvestrant in Participants With HR-Positive, HER2-Negative, PIK3CA Mutated, Locally Advanced or Metastatic Breast Cancer Post CDK4/6i and Endocrine Combination Therapy
Fase 3Hoffmann-La Roche
Condiciones: Breast Cancer
Sedes en Guadalajara: Panamerican Clinical Research S.A de C.V. · RENATI INNOVATION S.A.P.I. de C.V
Ver ficha informativaReclutandoNCT05899608
Clinical Study of Ivonescimab for First-line Treatment of Metastatic NSCLC Patients
Fase 3Summit Therapeutics
Condiciones: Non-Small Cell Lung Cancer
Sedes en Guadalajara: Panamerican Clinical Research S.A de C.V. · Actualidad Basada en Investigación del Cáncer · Renati Innovation S.A.P.I. DE C.V.
Ver ficha informativaReclutandoNCT06119581
A Study of First-Line Olomorasib (LY3537982) and Pembrolizumab With or Without Chemotherapy in Patients With Advanced KRAS G12C-Mutant Non-small Cell Lung Cancer
Fase 3Eli Lilly and Company
Condiciones: Carcinoma, Non-Small-Cell Lung, Neoplasm Metastasis
Sedes en Guadalajara: CIO - Centro de Inmuno-Oncología de Occidente · PanAmerican Clinical Research - Guadalajara · Actualidad Basada en la Investigación del Cáncer
Ver ficha informativaReclutandoNCT06136650
A Study of Opevesostat (MK-5684) Versus Alternative Next-generation Hormonal Agent (NHA) in Metastatic Castration-resistant Prostate Cancer (mCRPC) Post One NHA (MK-5684-004)
Fase 3Merck Sharp & Dohme LLC
Condiciones: Metastatic Castration-resistant Prostate Cancer (mCRPC), Prostatic Neoplasms
Sedes en Guadalajara: CIO - Centro de Inmuno-Oncología de Occidente ( Site 0928)
Ver ficha informativaReclutandoNCT06750094
A Study of Amivantamab and FOLFIRI Versus Cetuximab/Bevacizumab and FOLFIRI in Participants With KRAS/NRAS and BRAF Wild-type Colorectal Cancer Who Have Previously Received Chemotherapy
Fase 3Janssen Research & Development, LLC
Condiciones: Colorectal Neoplasms
Sedes en Guadalajara: Actualidad Basada En La Investigacion Del Cancer
Ver registro oficial ↗ReclutandoNCT06790693
A Study Evaluating the Efficacy and Safety of Inavolisib Plus CDK4/6 Inhibitor and Letrozole vs Placebo + CDK4/6i and Letrozole in Participants With Endocrine-Sensitive PIK3CA-Mutated, Hormone Receptor-Positive, HER2-Negative Advanced Breast Cancer
Fase 3Hoffmann-La Roche
Condiciones: Breast Cancer
Sedes en Guadalajara: Antiguo Hospital Civil de Guadalajara Fray Antonio Alcalde
Ver registro oficial ↗ReclutandoNCT06824467
A Study to Evaluate the Efficacy and Safety of Sacituzumab Tirumotecan (MK-2870) Maintenance Treatment Versus Standard of Care in Participants With Platinum-sensitive Recurrent Ovarian Cancer (MK-2870-022/TroFuse-022/ENGOT-ov84/GOG-3103)
Fase 3Merck Sharp & Dohme LLC
Condiciones: Ovarian Cancer, Fallopian Tube Cancer, Primary Peritoneal Cancer
Sedes en Guadalajara: CIO - Centro de Inmuno-Oncología de Occidente ( Site 1719)
Ver registro oficial ↗ReclutandoNCT06841354
A Study of Sacituzumab Tirumotecan (Sac-TMT, MK-2870) as Monotherapy and in Combination With Pembrolizumab (MK-3475) in Participants With Triple-Negative Breast Cancer (MK-2870-011/TroFuse-011)
Fase 3Merck Sharp & Dohme LLC
Condiciones: Triple Negative Breast Neoplasms
Sedes en Guadalajara: CIO - Centro de Inmuno-Oncología de Occidente ( Site 2504)
Ver ficha informativa